Finance

Beta
Lists
BBIO:NASDAQ
BridgeBio Pharma Inc
$69.38
+1.09%
(+0.75) 1D
$69.36
-0.03% (-0.020)
After hours
Closed: Jun 24, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBIO...
Open
$69.25
High
$70.77
Low
$68.94
Mkt. cap
13.59B
Avg. vol.
2.78M
Volume
4.19M
52-wk high
$84.94
52-wk low
$41.80
EPS
-$3.75
Beta
0.97
Shares outstanding
195.86M
No. of employees
837
Open
$69.25
High
$70.77
Low
$68.94
Mkt. cap
13.59B
Avg. vol.
2.78M
Volume
4.19M
52-wk high
$84.94
52-wk low
$41.80
EPS
-$3.75
Beta
0.97
Shares outstanding
195.86M
No. of employees
837
News stories
From sources across the web
About BridgeBio Pharma Inc
CEONeil Kumar
Employees837
Founded2015
HeadquartersPalo Alto, California, United States
SectorBiotechnology
Websitebridgebio.com
Analyst Ratings
Based on 19 analysts giving stock ratings to BBIO in the past 3 months
Strong Buy
Buy
18
Hold
1
Sell
0
12 month forecast
Based on 19 Wall Street analysts offering 12 month price targets for BBIO in the last 3 months.
Highest
Current $69.38
$157.00 (+126.29%)
Average
$106.22 (+53.10%)
Lowest
$82.00 (+18.19%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Salim Syed
Mizuho Securities
Buy
Maintained
$96.00
+38.4%
06/21/2026
Tiago Fauth
Raymond James
Buy
Maintained
$98.00
+41.3%
06/17/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$101.00
+45.6%
06/11/2026
Eliana Merle
Barclays
Buy
Maintained
$157.00
+126.3%
06/05/2026
Whitney Ijem
Canaccord Genuity
Buy
Initiated
$104.00
+49.9%
06/03/2026
Eric Joseph
Citi
Hold
Maintained
$82.00
+18.2%
06/01/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$110.00
+58.5%
05/28/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
$98.00
+41.3%
05/27/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
05/27/2026
Martin Auster
Raymond James
Hold
Downgraded
-
-
05/26/2026
Unknown Analyst
Citi
Hold
Initiated
-
-
05/19/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$100.00
+44.1%
05/12/2026
Biren Amin
Piper Sandler
Buy
Maintained
$111.00
+60%
05/12/2026
Danielle Brill
Truist Financial
Buy
Reiterated
$102.00
+47%
05/11/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$98.00
+41.3%
05/09/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$130.00
+87.4%
05/08/2026
Luca Issi
RBC Capital
Buy
Maintained
$100.00
+44.1%
05/07/2026
William Pickering
Bernstein
Buy
Reiterated
$114.00
+64.3%
05/08/2026
Paul Choi
Goldman Sachs
Buy
Maintained
$116.00
+67.2%
05/08/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$95.00
+36.9%
05/07/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
05/02/2026
Lisa Walter
RBC Capital
Buy
Initiated
$100.00
+44.1%
04/08/2026
Andrew Tsai
Jefferies
Buy
Maintained
$100.00
+44.1%
03/31/2026
Trevor Allred
Oppenheimer
Buy
Maintained
$81.00
+16.7%
02/25/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$110.00
+58.5%
02/25/2026
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.84 / -$0.62
-36.22%miss
Revenue / Est. (USD)
194.52M / 176.97M
+9.92%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
110.56M
120.70M
154.18M
194.52M
Cost of goods sold
3.65M
6.56M
8.11M
9.94M
Cost of revenue
3.65M
6.56M
8.11M
9.94M
Research and development expenses
111.23M
112.87M
116.42M
126.64M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
129.15M
137.62M
158.08M
163.90M
Operating expense
240.38M
250.50M
274.50M
290.53M
Total operating expenses
244.04M
257.06M
282.61M
300.47M
Operating income
-133.47M
-136.36M
-128.43M
-105.96M
Other non operating income
6.55M
16.46M
11.82M
4.25M
EBT including unusual items
-181.66M
-186.48M
-194.76M
-166.56M
EBT excluding unusual items
-180.85M
-177.64M
-183.62M
-166.56M
Income tax expense
2.10M
-1.54M
-120.00K
-
Effective tax rate
-1.16%
0.83%
0.06%
-
Other operating expenses
-
-
-
-
Net income
-181.90M
-182.74M
-192.86M
-164.04M
Net profit margin
-164.52%
-151.40%
-125.09%
-84.33%
Earnings per share
-0.95
-0.72
-0.94
-0.84
Interest and investment income
3.90M
6.24M
4.33M
6.25M
Interest expense
-37.64M
-48.15M
-50.31M
-52.82M
Net interest expenses
-33.74M
-41.91M
-45.98M
-46.57M
Depreciation and amortization charges
-
-
-
-
EBITDA
-132.16M
-134.96M
-127.00M
-104.77M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer